Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Now CROs require authorisation from Central Licencing Authority

    As per new amendment of New Drugs and Clinical Trials, Clinical Research Organisations cannot conduct any clinical trial or bioavailability studies without permission from Central Licencing Authority.

    As per new amendment, application for registration of Clinical Research Organisation for the purpose of conducting clinical trial or bioavailability or bioequivalence study with the Central Licencing Authority shall be made to the said authority in Form CT-07B.

  • Astellas VEOZAHTM (fezolinetant) approved by USFDA for Treatment of Vasomotor Symptoms Due to Menopause

    Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1 on May 12. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.

  • Zydus receives EIR for the Pre-Approval Inspection at the manufacturing facility in Moraiya, Ahmedabad

    The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life- sciences through quality healthcare solutions that impact lives.

  • CRISPR and Single-cell Sequencing Pinpoint Causal Genetic Variants for Traits and Diseases

    A major challenge in human genetics is understanding which parts of the genome drive specific traits or contribute to disease risk. This challenge is even greater for genetic variants found in the 98% of the genome that does not encode proteins.

    A new approach developed by researchers at New York University and the New York Genome Center combines genetic association studies, gene editing, and single-cell sequencing to address these challenges and discover causal variants and genetic mechanisms for blood cell traits.

  • 6th Annual Pharma Project & Portfolio Management 2023

    The 6th edition of the Pharma Project Portfolio Management set very high benchmarks in the originality and creativity of the session and delivered an exciting program filled with learning and experiences. This three-day in-person conference was held at Fairfield by Marriott near the Mumbai International Airport from 26th to 28th April 2023. The program was designed uniquely by balancing the various discussion topics between the project and portfolio management teams.

  • UCF Scientist Uncovers Roots of Antibiotic Resistance

    Bacteria naturally adapt to various environmental stimuli and as they mutate, these changes can make them resistant to drugs that would kill or slow their growth.

    In a recent article published in PLoS Genetics, UCF College of Medicine microbiologist Salvador Almagro-Moreno uncovers the evolutionary origins of antimicrobial resistance (AMR) in bacteria. His studies on the bacterium that causes cholera, Vibrio cholerae, provide insight into deciphering what conditions must occur for infectious agents to become resistant.

  • T Cells Can Activate Themselves to Fight Tumors

    When you need a bit of motivation, it often has to come from within. New research suggests cancer-fighting immune cells have found a way to do just that.

    Scientists at University of California San Diego have discovered a property of T cells that could inspire new anti-tumor therapeutics. Through a previously undescribed form of cell auto-signaling, T cells were shown to activate themselves in peripheral tissues, fueling their ability to attack tumors.

  • Lupin acquired French Pharmaceutical Company Medisol

    Global pharma major Lupin Limited announced that it has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance.

  • Dr. Reddy's Labs launches Regadenoson Injection in the USA

    Dr. Reddy's Laboratories Ltd. launched Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan (Regadenoson) injection, approved by U.S. Food and Drug Administration (USFDA).

    Lexiscan is a registered trademark of Astellas US LLC. It is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.

  • Breakthrough for sweat : health monitoring device from UH researchers

    Sweat is more than just a sign of a good workout. It holds vital information about our health, providing clues to dehydration, fatigue, blood sugar levels and even serious conditions such as cystic fibrosis, diabetes and heart failure. Researchers at the University of Hawaiʻi at Mānoa College of Engineering have taken a giant leap forward in sweat analysis with an innovative 3D-printed wearable sweat sensor called the “sweatainer.”

Subscribe to Pharma News